PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

PTC Therapeutics (NASDAQ: PTCT) approved inducement equity awards on March 10, 2026, for 18 new employees: 14,550 non‑statutory stock options and 17,515 restricted stock units (RSUs) as hiring incentives under Nasdaq Listing Rule 5635(c)(4).

Options carry a $68.56 exercise price, a 10‑year term, and four‑year vesting (25% after one year, then quarterly 6.25%). RSUs vest over four years with 25% vesting each anniversary, all subject to continued service.

Key Figures

Stock options granted: 14,550 shares RSUs granted: 17,515 RSUs New employees: 18 employees +5 more

8 metrics

Stock options granted 14,550 shares Non-statutory stock options approved on March 10, 2026

RSUs granted 17,515 RSUs Inducement grants to new employees

New employees 18 employees Recipients of stock options and RSUs

Option exercise price $68.56 per share Closing price on March 10, 2026 grant date

Option term 10 years Duration of non-statutory stock options

Option vesting schedule 25% then 6.25% quarterly Vests over four years, service-based

RSU vesting schedule 25% annually RSUs vest over four years on hire-date anniversaries

Current price vs 52-week range $64.49 26.3% below 52-week high; above 52-week low

Market Reality Check

Price: $63.36 Vol: Volume 605,683 is below t...

low vol

$63.36 Last Close

Volume Volume 605,683 is below the 20-day average of 1,274,097 (relative volume 0.48x) ahead of this filing-style news. low

Technical Shares at $64.49 are trading slightly above the 200-day MA of $63.22, indicating a position just above longer-term trend before this announcement.

Peers on Argus

PTCT was down 3.52% while several biotech peers also traded lower: RNA -4.98%, C...

PTCT was down 3.52% while several biotech peers also traded lower: RNA -4.98%, CRSP -1.91%, MRUS -7.08%, KRYS -2.94%, with TGTX an outlier at +2.91%, suggesting a broader pressure in parts of the biotechnology group rather than news-specific impact.

Historical Context

5 past events · Latest: 2026-02-23 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
2026-02-23	Investor conferences	Neutral	-0.2%	Outlined participation in three March investor conferences with webcast access.
2026-02-19	Earnings and update	Positive	+1.1%	Reported strong 2025 revenues, cash balance, and collaboration-related income.
2026-02-18	Sector market report	Neutral	+1.4%	Third-party outlook on the phenylketonuria market including emerging therapies.
2026-02-12	Regulatory setback	Negative	-1.8%	Withdrew Translarna NDA resubmission after FDA feedback on efficacy evidence.
2026-02-05	Earnings date notice	Neutral	-2.1%	Announced timing and webcast details for upcoming Q4 and full-year results.

Pattern Detected

Recent headlines show price reactions generally aligning with the tone of news, with negative regulatory updates and positive earnings eliciting moves in the expected direction.

Recent Company History

Over recent months, PTC issued a mix of corporate and regulatory updates. An earnings release on 2026-02-19 detailed substantial 2025 revenue and net income and was followed by a modest positive move. A regulatory setback for Translarna on 2026-02-12 coincided with a negative reaction. Conference participation and scheduling releases drew only small moves. Today’s inducement grants fit into a pattern of routine corporate disclosures alongside more material financial and regulatory events.

Market Pulse Summary

This announcement described routine inducement equity awards for 18 new employees, including options...

Analysis

This announcement described routine inducement equity awards for 18 new employees, including options on 14,550 shares and 17,515 RSUs at an exercise price of $68.56, vesting over four years. In recent months, more material drivers included a detailed 2025 earnings update and a regulatory setback for Translarna. Investors may focus less on these compensation mechanics and more on upcoming financial and regulatory milestones when assessing the company’s trajectory.

Key Terms

non-statutory stock options, restricted stock units, nasdaq listing rule 5635(c)(4), inducement grant exception, +2 more

6 terms

non-statutory stock options financial

"approved non-statutory stock options to purchase an aggregate of 14,550 shares"

Non-statutory stock options are a type of reward that companies give to employees, allowing them to buy company shares at a set price within a certain period. Unlike formal or government-approved plans, these options are more flexible but may have different tax implications. For investors, they can influence a company's stock price and financial health, making them an important factor to consider.

restricted stock units financial

"and 17,515 restricted stock units ("RSUs"), each representing the right"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"pursuant to the Nasdaq inducement grant exception ... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement grant exception regulatory

"The awards were made pursuant to the Nasdaq inducement grant exception as a component"

An inducement grant exception is a regulatory allowance that lets a publicly traded company give stock-based awards to a newly hired employee outside the company’s existing, shareholder-approved equity plan — essentially a signing bonus paid in shares or options. Investors care because these grants can dilute existing shareholders, change executive incentives, and signal the company is using equity to attract key talent, so they are usually disclosed and subject to specific limits and board approval.

exercise price financial

"All stock option awards have an exercise price of $68.56 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"each representing the right to receive one share of its common stock upon vesting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. Not financial advice.

WARREN, N.J., March 13, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 10, 2026, the company approved non-statutory stock options to purchase an aggregate of 14,550 shares of its common stock and 17,515 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 18 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation.

The inducement grants were approved by PTC's Compensation Committee on March 10, 2026, and are being made as an inducement material to each employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

All stock option awards have an exercise price of $68.56 per share, the closing price of PTC's common stock on March 10, 2026, the date of the grant. The stock options each have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's new hire date and 6.25% of the original number of shares vesting at the end of each subsequent three-month period thereafter until fully vested, subject to the employee's continued service with the company through the applicable vesting dates. The RSUs each will vest over four years, with 25% of the original number of shares vesting on each annual anniversary of the applicable employee's new hire date until fully vested, subject to the employee's continued service with the company through the applicable vesting dates.

About PTC Therapeutics, Inc. 
PTC is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. PTC is advancing a robust and diversified pipeline of transformative medicines as part of its mission to provide access to best-in-class treatments for patients with unmet medical needs. The company's strategy is to leverage its scientific expertise and global commercial infrastructure to optimize value for patients and other stakeholders. To learn more about PTC, please visit www.ptcbio.com and follow us on LinkedIn, X, Instagram and Facebook.

For more information, please contact:

Investors:
Ellen Cavaleri
+1 (615) 618-8228
ecavaleri@ptcbio.com

Media:
Jeanine Clemente
+1 (908) 912-9406
jclemente@ptcbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302712038.html

SOURCE PTC Therapeutics, Inc.

FAQ

What inducement grants did PTC Therapeutics (PTCT) approve on March 10, 2026?

PTC approved 14,550 non‑statutory stock options and 17,515 RSUs for 18 new hires. According to the company, these awards were granted as inducement compensation under Nasdaq Listing Rule 5635(c)(4).

What are the exercise price and term for the PTCT stock options granted March 10, 2026?

The stock options have an exercise price of $68.56 and a 10‑year term. According to the company, $68.56 was the closing price per share on March 10, 2026, the grant date.

How do the PTCT options and RSUs vest for new employees granted March 10, 2026?

Options vest 25% after one year, then 6.25% quarterly until fully vested over four years. According to the company, RSUs vest 25% each year on the anniversary for four years.

How many employees received inducement awards from PTC Therapeutics (PTCT) on March 10, 2026?

Eighteen new employees received inducement awards. According to the company, the awards were material to each employee's acceptance of employment under Nasdaq rules.

Are the PTCT inducement grants subject to service conditions or other requirements?

Yes, all awards vest only with continued service through applicable vesting dates. According to the company, vesting is contingent on each employee remaining employed through each scheduled vesting date.